Aetna Updates Benign Prostatic Hyperplasia Coverage Policy (CPB 0079) — What Billing Teams Need to Know
Aetna has modified its Clinical Policy Bulletin for Benign Prostatic Hyperplasia (CPB 0079), with an effective date of January 14, 2026. This update affects urology and urogynecology billing teams, as well as any practice performing BPH-related procedures—from minimally invasive surgical therapies to pharmacologic management billed under medical benefit. If your revenue cycle includes BPH treatments, this policy warrants a close review before you submit another claim.
| Field | Detail |
|---|---|
| Payer | Aetna |
| Policy | Benign Prostatic Hyperplasia — CPB 0079 |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | 2026-01-14 |
| Impact Level | High |
| Specialties Affected | Urology, Primary Care, Interventional Radiology, Ambulatory Surgery Centers |
| Key Action | Review all BPH procedure workflows against the updated CPB 0079 criteria before submitting January 2026 claims. |
What Is Aetna's CPB 0079 and Why Does It Matter for BPH Billing?
Aetna, a CVS Health company, publishes Clinical Policy Bulletins (CPBs) to define coverage criteria, medical necessity standards, and experimental/investigational designations for specific conditions and procedures. CPB 0079 covers the full spectrum of Benign Prostatic Hyperplasia treatment—one of the highest-volume condition categories in urology billing.
BPH is among the most common conditions treated in men over 50, and the treatment landscape has expanded significantly over the past several years. Minimally invasive surgical therapies (MISTs) such as UroLift, Rezūm water vapor therapy, and aquablation have joined more established procedures like transurethral resection of the prostate (TURP) on coverage consideration lists. Each iteration of this policy can shift which of those procedures Aetna deems medically necessary, investigational, or subject to prior authorization.
Because the full revised policy text was not available at time of publication, billing teams should pull the current version directly from Aetna's website or through PayerPolicy's policy viewer to confirm specific criteria changes. What follows is a framework based on CPB 0079's known structure and the types of changes typically seen in BPH policy modifications.
Aetna BPH Coverage: Understanding the Policy Structure
Historically, CPB 0079 has organized BPH coverage into several categories that billing teams need to distinguish clearly:
Medically necessary procedures are those Aetna covers when documented medical necessity criteria are met. For BPH, this has typically included procedures like TURP, laser prostatectomy (including holmium laser enucleation of the prostate, or HoLEP), and certain MISTs when conservative management has failed and symptom severity thresholds are documented.
Experimental and investigational (E&I) designations are assigned to procedures Aetna considers insufficiently supported by clinical evidence. Procedures landing in this category face near-certain denial regardless of diagnosis coding. In past versions of CPB 0079, certain newer ablative techniques have carried E&I status—and policy modifications often involve moving procedures in or out of this category as evidence matures.
Prior authorization requirements are a critical operational concern. BPH surgical procedures typically require prior auth from Aetna, and modifications to the policy's medical necessity criteria directly affect what clinical documentation supports an approved auth request. An updated policy means your prior auth submission templates may need updating too.
Medical Necessity Criteria Typically Applied Under CPB 0079
While the specific updated criteria from this January 2026 modification require direct confirmation from the policy document, CPB 0079 has historically required documentation of criteria including:
| # | Covered Indication |
|---|---|
| 1 | Symptom severity: Documented moderate-to-severe lower urinary tract symptoms (LUTS), often quantified via the International Prostate Symptom Score (IPSS) |
| 2 | Failure of conservative management: Documentation that watchful waiting and/or pharmacologic therapy (alpha-blockers, 5-alpha reductase inhibitors) has been trialed and failed, or is contraindicated |
| 3 | Urodynamic findings: In some procedure categories, urodynamic testing or post-void residual measurements have been required to establish obstruction |
| 4 | Prostate size thresholds: Certain procedures—particularly aquablation and HoLEP—have size criteria that must be documented in the medical record |
| 5 | Absence of active prostate cancer: Procedures are typically covered for BPH only when malignancy has been ruled out |
Any modifications to these thresholds in the January 2026 update could affect claims currently in your queue. A prior auth that was approved under the old criteria does not automatically guarantee continued coverage if the patient hasn't yet had the procedure.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
Affected Codes
The January 14, 2026 version of CPB 0079 was not accompanied by a published code list in the data available at time of writing. This policy does not list specific CPT, HCPCS, or ICD-10 codes in the data provided to us. Billing teams should access the full policy document to confirm the complete code list.
For reference, CPB 0079 has historically referenced procedures in the following general categories—but do not use this as a substitute for the actual policy code list:
Common BPH Procedure Code Categories (verify against current policy):
| Category | Code Type | Notes |
|---|---|---|
| Transurethral resection of the prostate (TURP) | CPT | Historically covered with criteria |
| Laser prostatectomy / HoLEP | CPT | Coverage status varies by technique |
| Prostatic urethral lift (UroLift) | CPT | Has moved between covered/E&I in prior versions |
| Water vapor thermal therapy (Rezūm) | CPT | Review current E&I status in updated policy |
| Aquablation therapy | CPT | Newer entrant; verify current coverage designation |
| Transurethral microwave thermotherapy (TUMT) | CPT | Has historically had coverage restrictions |
You must confirm actual CPT codes and their current coverage status directly from the updated CPB 0079 document. Billing based on assumed continuity from a prior policy version is a compliance risk.
What Your Billing Team Should Do
| # | Action Item |
|---|---|
| 1 | Pull the full updated CPB 0079 immediately. Access the current policy at Aetna's clinical policy library or through PayerPolicy's policy viewer at app.payerpolicy.org/p/aetna/0079. Identify every section that has been modified from the prior version — pay particular attention to the E&I list and the medical necessity criteria section. |
| 2 | Audit your pending prior auth queue for BPH procedures. Any prior auth submitted before January 14, 2026 that hasn't yet resulted in a procedure should be re-evaluated against the new criteria. If the criteria have changed, you may need to supplement your documentation or resubmit. |
| 3 | Update your clinical documentation checklists for BPH procedures. Work with your urology providers to ensure that operative notes, office visit documentation, and pre-authorization requests capture all criteria elements required under the updated policy — IPSS scores, prior treatment history, prostate volume measurements, and urodynamic findings where applicable. |
| 4 | Flag any BPH procedure that has previously been designated E&I. If the policy modification has changed the coverage status of a specific procedure your practice performs, brief your providers and update your scheduling workflows to reflect whether prior auth is now required—or whether a procedure previously denied may now be covered. |
| 5 | Set a 60-day denial monitoring flag for BPH claims. Policy changes frequently produce a wave of denials as payer systems update. Flag all BPH claims submitted between January 14 and March 14, 2026 for secondary review. If you see denial patterns that don't align with the updated criteria, escalate to your payer relations contact. |
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.